NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on US National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19 – QNT Press Release

  • Based on a review of nearly 75% of the target enrollment of 640 patients, most of which have reached 90 days, the Independent DSMB overseeing the ACTIV-3b (TESICO) study determined that evaluation of aviptadil should cease due to futility
  • ZYESAMI® (aviptadil) was the sole remaining investigational medicine in ACTIV-3b targeted at Critical COVID-19 patients
  • ACTIV-3b Critical Care Study evaluated ZYESAMI and Veklury® (remdesivir), in Critical COVID-19 Patients, as monotherapy and in combination against placebo
  • The DSMB stated there were no safety concerns for aviptadil

RADNOR, Pa., May 25, 2022 /PRNewswire/ — NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (“NRx Pharmaceuticals”), a clinical-stage biopharmaceutical company, today announced results of a review conducted by the Data Safety and Monitoring Board (DSMB) on May 25, 2022. The DSMB reviewed data of approximately 460 patients with Critical COVID- 19 Respiratory Failure who were enrolled in the ACTIV-3b (TESICO) trial, most of which had reached the 90-day endpoint. The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Full story available on

Source link

Recommended For You

About the Author: News Center